Granulomonocytic progenitors are key target cells of azacytidine in higher risk myelodysplastic syndromes and acute myeloid leukemia

[1]  P. Vyas,et al.  Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature , 2017, Clinical Cancer Research.

[2]  Susan R. Wilson,et al.  Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes. , 2017, Cell reports.

[3]  H. Deeg,et al.  Mutational analysis in serial marrow samples during azacitidine treatment in patients with post-transplant relapse of acute myeloid leukemia or myelodysplastic syndromes , 2017, Haematologica.

[4]  Francine E. Garrett-Bakelman,et al.  Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2- and TET2-Mutant Acute Myeloid Leukemia. , 2017, Cancer discovery.

[5]  Christopher A. Miller,et al.  Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy. , 2017, Blood.

[6]  Christopher A. Miller,et al.  Dynamic Changes in the Clonal Structure of MDS and AML in Response to Epigenetic Therapy , 2016, Leukemia.

[7]  Christopher A. Miller,et al.  TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. , 2016, The New England journal of medicine.

[8]  I. Weissman,et al.  Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia , 2013, Leukemia.

[9]  P. Vyas,et al.  Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. , 2011, Cancer cell.

[10]  B. Quesnel,et al.  Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). , 2010, Blood.

[11]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[12]  M. Lübbert,et al.  Nonclonal neutrophil responses after successful treatment of myelodysplasia with low-dose 5-aza-2'-deoxycytidine (decitabine). , 2004, Leukemia research.